RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures a...
RxElite reported revenue of $2.81 million for fiscal year 2007, up 139.0% from fiscal year 2006, and net income of -$17.17 million. In Q3 2008 (the quarter ended September 30, 2008) revenue was $3.26 million, up 332.1% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2007.
No profile data available.